In the latest trading session, 4.76 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.84. With the company’s most recent per share price at $6.55 changed hands at -$0.33 or -4.87% at last look, the market valuation stands at $2.56B. RXRX’s current price is a discount, trading about -140.31% off its 52-week high of $15.74. The share price had its 52-week low at $5.60, which suggests the last value was 14.5% up since then. When we look at Recursion Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 15.67 million shares, with the 3-month average coming to 11.39 million.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.43. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.41.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in red as seen in intraday trades today. With action -16.09%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.18%, with the 5-day performance at -16.09% in the red. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -12.27% down. Looking at the short shares, we see there were 67.1 million shares sold at short interest cover period of 4.72 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 40.45% from its recent market value. According to analyst projections, RXRX’s forecast low is 6 with 12 as the target high. To hit the forecast high, the stock’s price needs a -83.21% plunge from its current level, while the stock would need to tank 8.4% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Data shows that the Recursion Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -21.71% over the past 6 months, a 1.27% in annual growth rate that is considerably lower than the industry average of 16.20%. Year-over-year growth is forecast to reach 50.61% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 18.17M. 3 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the current quarter will be 12M. The company’s revenue for the corresponding quarters a year ago was 10.89M and 13.79M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 66.85%. The estimates for the next quarter sales put growth at -13.01%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.41%. The 2025 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 2.85%.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report in February.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.50% of Recursion Pharmaceuticals Inc shares while 69.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 71.55%. There are 69.04% institutions holding the Recursion Pharmaceuticals Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 11.924% of the shares, roughly 28.14 million RXRX shares worth $211.07 million.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. With 19.4 shares estimated at $125.81 million under it, the former controlled 5.06% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 3.27% of the shares, roughly 12.54 shares worth around $81.29 million.
